These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 28758379

  • 1. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
    Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS.
    J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
    [Abstract] [Full Text] [Related]

  • 2. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N.
    J Clin Oncol; 2015 Aug 01; 33(22):2457-63. PubMed ID: 26124480
    [Abstract] [Full Text] [Related]

  • 3. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).
    Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE.
    Int J Gynecol Pathol; 2019 May 01; 38(3):230-240. PubMed ID: 29750700
    [Abstract] [Full Text] [Related]

  • 4. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
    Singh P, Kaushal V, Rai B, Rajwanshi A, Gupta N, Dey P, Garg R, Rohilla M, Suri V, Ghoshal S, Srinivasan R.
    Histopathology; 2018 Mar 01; 72(4):619-625. PubMed ID: 28914967
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay MHE, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA.
    Int J Gynecol Cancer; 2017 May 01; 27(4):708-713. PubMed ID: 28441251
    [Abstract] [Full Text] [Related]

  • 6. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF, HGSC CRS Collaborative Network (Supplementary 1), Singh N.
    Gynecol Oncol; 2019 Aug 01; 154(2):441-448. PubMed ID: 31118141
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS, Lee JY, Kim HS, Nam EJ, Kim SW, Kim YT.
    Yonsei Med J; 2018 Oct 01; 59(8):930-936. PubMed ID: 30187699
    [Abstract] [Full Text] [Related]

  • 9. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A.
    Am J Surg Pathol; 2020 Feb 01; 44(2):206-213. PubMed ID: 31651523
    [Abstract] [Full Text] [Related]

  • 10. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S, Polson A, Nath R, Lane G, Sayasneh A, Jakes A, Begum S, Mehra G.
    Gynecol Oncol; 2018 Nov 01; 151(2):264-268. PubMed ID: 30197060
    [Abstract] [Full Text] [Related]

  • 11. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM, Chi DS.
    Gynecol Oncol; 2017 Apr 01; 145(1):15-20. PubMed ID: 28238354
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J, Liu N, Zhang A, Bao X.
    J Obstet Gynaecol Res; 2018 Sep 01; 44(9):1808-1816. PubMed ID: 30019801
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Ren B, Guo W, Chen X.
    J Ovarian Res; 2016 Dec 02; 9(1):85. PubMed ID: 27912779
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
    Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S, EORTC, MRC CHORUS study investigators.
    Lancet Oncol; 2018 Dec 02; 19(12):1680-1687. PubMed ID: 30413383
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.